ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
from Sanofi - Aventis Groupe https://ift.tt/oP24pdr
via IFTTT
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
https://ift.tt/NytGSV9
from Sanofi - Aventis Groupe https://ift.tt/oP24pdr
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/oP24pdr
via IFTTT
0 Comments
Please ,
Do not enter any kind of span link